CA
NZ
UK
AU
IND
US
Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) has compressed a year of corporate news into five weeks: positive mid-stage clinical data, a formal search for a partner to fund the expensive part, and quarterly accounts showing how little time it has to close that deal.
Tenon Medical, Inc. (NASDAQ:TNON) makes implants that fuse the sacroiliac joint, the load-bearing hinge where the base of the spine meets the pelvis and an under-diagnosed source of chronic lower-back pain. The Los Gatos, California company has spent six weeks growing sales faster than …
Reviva Pharmaceuticals Holdings, Inc. (OTCQB:RVPH) is a Cupertino, California clinical-stage drug developer whoseInvestmentcase rests almost entirely on one molecule: brilaroxazine, an experimental once-daily pill for schizophrenia.
IceCure Medical Ltd. (NASDAQ:ICCM), the Israeli developer of the ProSense liquid-nitrogen cryoablation system, is trying to prove a hard-won U.S. clearance can turn into revenue. On 12 August 2026 it reported first-half sales up about 45% year over year, its strongest growth since the …
Intensity Therapeutics, Inc. (NASDAQ:INTS) spent much of the past 18 months with both of its lead cancer studies standing still. One was halted for money, the other for safety. In July it began dosing patients again in the smaller of the two, and on …
Moleculin Biotech, Inc. (NASDAQ:MBRX) did two things on the same July morning that small drug developers usually do months apart: it released a fresh interim look at the most important trial it has ever run, and priced a stock sale to help pay for …
Quoin Pharmaceuticals, Ltd. (NASDAQ:QNRX) is among the smallest US-listed rare-disease biotechs, and it has spent three months stacking up regulatory milestones at a pace few micro-caps manage. The Israeli-incorporated group, run from Ashburn, Virginia, trades through American Depositary Shares representing 35 ordinary shares each.
SeaStar Medical Holding Corporation (NASDAQ:ICU) is trying to prove a product with clinical traction can outrun a shrinking bank balance. The Denver-based company sells QUELIMMUNE, a blood-filtering cartridge approved by the FDA in February 2024 under a Humanitarian Device Exemption, a pathway reserved for …
Sunshine Biopharma, Inc. (NASDAQ:SBFM) filed its second-quarter report on 13 August 2026, and it lands at an awkward moment for a company that spent the summer stacking up regulatory wins. The commercial engine, Canadian generics subsidiary Nora Pharma Inc., is still turning out roughly …
Senti Biosciences Holdings, Inc. (NASDAQ:SNTI) spent early 2026 reporting encouraging cancer data, then agreed to sell the programme that produced it. Its lead candidate, SENTI-202, is an off-the-shelf CAR-NK cell therapy for relapsed or refractory acute myeloid leukaemia (AML), built on engineered genetic circuits …
Please wait processing your request...